14 [67] H. C. Hsu, Y. M. Jeng, T. L. Mao, J. S. Chu, P. L. Lai, and S. Y. Peng, “β-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis,” American Journal of Pathology, vol. 157, no. 3, pp. 763–770, 2000. [68] B. Cieply, G. Zeng, T. Proverbs-Singh, D. A. Geller, and S. P. S. Monga, “Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene,” Hepatology, vol. 49, no. 3, pp. 821–831, 2009. [69] D. Gouas, H. Shi, and P. Hainaut, “The aﬂatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of expo- sure, early detection and target for therapy,” Cancer Letters, vol. 286, no. 1, pp. 29–37, 2009. [70] Y. Hoshida, S. Toﬀanin, A. Lachenmayer, A. Villanueva, B. Minguez, and J. M. Llovet, “Molecular classiﬁcation and novel targets in hepatocellular carcinoma: recent advance- ments,” Seminars in Liver Disease, vol. 30, no. 1, pp. 35–51, 2010. [71] O. M. Andrisani, L. Studach, and P. Merle, “Gene signatures in hepatocellular carcinoma (HCC),” Seminars in Cancer Biology, vol. 21, no. 1, pp. 4–9, 2011. [72] J. S. Lee, I. S. Chu, J. Heo et al., “Classiﬁcation and prediction of survival in hepatocellular carcinoma by gene expression proﬁling,” Hepatology, vol. 40, no. 3, pp. 667–676, 2004. [73] J. S. Lee, J. Heo, L. Libbrecht et al., “A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells,” Nature Medicine, vol. 12, no. 4, pp. 410–416, 2006. [74] S. Boyault, D. S. Rickman, A. De Reynie`s et al., “Transcrip- tome classiﬁcation of HCC is related to gene alterations and to new therapeutic targets,” Hepatology, vol. 45, no. 1, pp. 42– 52, 2007. [75] J. W. Kim, Q. Ye, M. Forgues et al., “Cancer-associated molecular signature in the tissue samples of patients with cirrhosis,” Hepatology, vol. 39, no. 2, pp. 518–527, 2004. [76] T. Yamashita, M. Forgues, W. Wang et al., “EpCAM and α- fetoprotein expression deﬁnes novel prognostic subtypes of hepatocellular carcinoma,” Cancer Research, vol. 68, no. 5, pp. 1451–1461, 2008. [77] L. X. Qin and Z. Y. Tang, “The prognostic signiﬁcance of clin- ical and pathological features in hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 8, no. 2, pp. 193–199, 2002. [78] Y. F. Shan, Y. L. Huang, Y. K. Xie et al., “Angiogenesis and clinicopathologic characteristics in diﬀerent hepatocel- lular carcinoma subtypes deﬁned by EpCAM and alpha- fetoprotein expression status,” Medical Oncology. In press. [79] T. Yamashita, J. Ji, A. Budhu et al., “EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features,” Gastroenterology, vol. 136, no. 3, pp. 1012–e4, 2009. [80] M. Ferracin, A. Veronese, and M. Negrini, “Micromarkers: MiRNAs in cancer diagnosis and prognosis,” Expert Review of Molecular Diagnostics, vol. 10, no. 3, pp. 297–308, 2010. [81] A. Budhu, H. L. Jia, M. Forgues et al., “Identiﬁcation of metastasis-related microRNAs in hepatocellular carcinoma,” Hepatology, vol. 47, no. 3, pp. 897–907, 2008. [82] J. Yao, L. Liang, S. Huang et al., “Microrna-30d promotes tumor invasion and metastasis by targeting galphai2 in hepa- tocellular carcinoma,” Hepatology, vol. 51, no. 3, pp. 846–856, 2010. Pathology Research International [83] C. C. Wong, C. Wong, E. K. Tung et al., “The MicroRNA miR- 139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating rho-kinase 2,” Gastroenterol- ogy, vol. 140, no. 1, pp. 322–331, 2011. [84] Y. Murakami, T. Yasuda, K. Saigo et al., “Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues,” Oncogene, vol. 25, no. 17, pp. 2537–2545, 2006. [85] C. Coulouarn, V. M. Factor, J. B. Andersen, M. E. Durkin, and S. S. Thorgeirsson, “Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties,” Oncogene, vol. 28, no. 40, pp. 3526–3536, 2009. [86] Y. Ladeiro, G. Couchy, C. Balabaud et al., “MicroRNA proﬁling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations,” Hepatology, vol. 47, no. 6, pp. 1955–1963, 2008. [87] S. Ura, M. Honda, T. Yamashita et al., “Diﬀerential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma,” Hepatology, vol. 49, no. 4, pp. 1098–1112, 2009. [88] G. E. Chung, J. H. Yoon, S. J. Myung et al., “High expression of microRNA-15b predicts a low risk of tumor recurrence following curative resection of hepatocellular carcinoma,” Oncology Reports, vol. 23, no. 1, pp. 113–119, 2010. [89] J. Ji, J. Shi, A. Budhu et al., “MicroRNA expression, survival, and response to interferon in liver cancer,” New England Journal of Medicine, vol. 361, no. 15, pp. 1437–1447, 2009. [90] Y. Xiong, J. H. Fang, J. P. Yun et al., “Eﬀects of microrna-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma,” Hepatology, vol. 51, no. 3, pp. 836–845, 2010. [91] J. Zhang, Y. Yang, T. Yang et al., “MicroRNA-22, down- regulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity,” British Journal of Cancer, vol. 103, no. 8, pp. 1215–1220, 2010. [92] J. Ji, T. Yamashita, A. Budhu et al., “Identiﬁcation of MicroRNA-181 by genome-wide screening as a critical player in EpCAM—positive hepatic cancer stem cells,” Hepatology, vol. 50, no. 2, pp. 472–480, 2009. [93] W. E. Naugler, T. Sakurai, S. Kim et al., “Gender disparity in liver cancer due to sex diﬀerences in MyD88-dependent IL-6 production,” Science, vol. 317, no. 5834, pp. 121–124, 2007. [94] B. Blechacz and G. J. Gores, “Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment,” Hepatology, vol. 48, no. 1, pp. 308–321, 2008. [95] R. Nishino, M. Honda, T. Yamashita et al., “Identiﬁcation of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma,” Journal of Hepatology, vol. 49, no. 2, pp. 207–216, 2008. [96] H. Francis, G. Alpini, and S. DeMorrow, “Recent advances in the regulation of cholangiocarcinoma growth,” American Journal of Physiology, vol. 299, no. 1, pp. G1–G9, 2010. [97] M. M. Yeh, “Pathology of combined hepatocellular- cholangiocarcinoma,” Journal of Gastroenterology and Hepa- tology, vol. 25, pp. 1485–1492, 2010. [98] N. D. Theise, O. Nakashima, Y. N. Park, and Y. Nakanuma, “Combined hepatocellular-cholangiocarcinoma,” in WHO Classiﬁcation of Tumours of the Digestive System, F. T. Bosman, F. Carneiro, R. H. Hruban, and N. D. Theise, Eds., pp. 225– 227, IARC, Lyon, France, 4th edition, 2010. [99] S. Tanaka, T. Yamamoto, H. Tanaka et al., “Potentiality of combined hepatocellular and intrahepatic cholangio- cellular carcinoma originating from a hepatic precursor